Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT07423988
Recruiting Not applicable

Evaluation of Changes in Sleep Efficiency Among PIC DU MIDI Staff Between Nights Spent at Home and Nights Spent in the Workplace Under High Altitude Conditions

NCT07423988 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2026-03-23
Last updated
2026-04-08

Condition(s) studied

Sleep Disorder (Disorder)

Investigational drug(s) / intervention(s)

Sleep recording

Sleep recording: Polysomnography and questionnaires.

Study summary

Sleep organization and cardiorespiratory parameters are disrupted in extreme conditions such as high altitude. The pathophysiology of medical problems related to acute high-altitude exposure is partially understood, but sleep quality indicators are very rarely measured under these conditions. This lack of information is even more pronounced among employees subjected to cyclical exposure to high-altitude hypoxic stress, as is the case for the employees at the Pic du Midi. These 32 employees regularly report to their occupational physician difficulties in managing their sleep disorders, struggling to distinguish symptoms from objective changes in their sleep cycles. Among them, 13 are on call at the summit of the Pic du Midi (2,877 m), while 19 work there during the day and return home to a lower altitude at night to sleep. The investigators also wish to measure structural changes in sleep and its cardiorespiratory parameters using polysomnography in these 13 employees, comparing nights spent at home at normal altitude with those spent at the summit of the Pic du Midi. These changes will also be compared to those of a group of 19 employees who do not sleep at high altitude..

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
Accepted
Inclusion Criteria: Group "with on-call night at high altitude at the Pic du Midi": * Employed at the Pic du Midi for at least one month * Working nights at high altitude (at the Pic du Midi, altitude of 2877m) as part of their professional activity * Person affiliated with or covered by a social security scheme * Free, informed, and written consent signed by the participant and the investigator Night group "without on-call night at high altitude": * Employed at the Pic du Midi for at least one month * Not working nights at high altitude (at the Pic du Midi, altitude of 2877m) as part of their professional activity * Person affiliated with or covered by a social security scheme social * Free, informed and written consent signed by the participant and the investigator Exclusion Criteria: * For all participants: * History of cardiovascular disease * Use of cardiovascular/psychotropic medication * Participant under legal guardianship or other protective regime (guardianship, curatorship) * Pregnant or breastfeeding woman * French language proficiency insufficient to complete the questionnaires

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Unité du sommeil, Hôpital Pierre Paul Riquet, 1 place du Docteur Baylac Toulouse Oui Recruiting

More University Hospital, Toulouse trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07423988 on ClinicalTrials.gov ↗ ← All trials in France